Company news
Aptose Biosciences Inc news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
Aptose Biosciences Announces Completion of Acquisition by Hanmi Pharmaceutical
June 30, 2026
Aptose Presents Safety, Response, and MRD Clinical Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2026 EHA Congress in Oral Presentation
June 15, 2026
Aptose Biosciences Announces Update on Anticipated Timing of Closing of the Plan of Arrangement with Hanmi Pharmaceutical
May 29, 2026
Aptose Reports First Quarter 2026 Results
May 13, 2026
Aptose Biosciences Announces Update on Anticipated Timing of Closing of the Plan of Arrangement with Hanmi Pharmaceutical
April 30, 2026
Aptose Biosciences Announces Results of Special Shareholders Meeting; Announces Receipt of Final Court Approval of Plan of Arrangement; Reports Year End 2025 Results and Corporate Highlights
March 31, 2026
Leading Independent Proxy Advisory Firm Glass Lewis Endorses Aptose Plan of Arrangement
March 23, 2026
Leading Independent Proxy Advisory Firm ISS Recommends Aptose Biosciences Shareholders Vote "FOR" Proposed Plan of Arrangement with Hanmi Pharmaceutical
March 19, 2026
Aptose Biosciences Announces Amendment to Arrangement Agreement and Details of Postponed Special Meeting of Shareholders
February 24, 2026
Aptose Biosciences Announces Rescheduling of Special Meeting of Shareholders to Approve the Acquisition by Hanmi Pending Final Clearance from SEC
December 19, 2025
Aptose's Tuspetinib Triple Drug Therapy Featured at the 2025 ASH Annual Meeting; High Rate of Frontline Clinical Responses Continues Across AML Populations
December 6, 2025
Aptose Biosciences Announces Arrangement Agreement for Acquisition by Hanmi Pharmaceutical
November 19, 2025
Aptose Reports Third Quarter 2025 Results
November 13, 2025
Aptose Biosciences Announces Results of Reconvened Annual and Special Shareholders Meeting and Appointment of Ernst & Young LLP as New Auditor
August 22, 2025
Aptose Selects Ernst & Young Global Limited as its New Independent Auditor and Calls Reconvened Meeting of its Shareholders
August 1, 2025
Aptose Biosciences announces results of annual and special meeting of shareholders
June 10, 2015
Aptose Biosciences Granted Orphan Drug Designation by the U.S. FDA for APTO-253 in Acute Myeloid Leukemia
June 2, 2015
Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015
May 5, 2015
Aptose Biosciences To Host First Quarter Ended March 31, 2015 Financial Results Conference Call and Webcast
April 30, 2015
Aptose Biosciences Announces Appointment of Dr. Michael Andreeff to Scientific Advisory Board
March 23, 2015
Aptose Biosciences to Present at the 12th Annual BIO Asia International Conference
March 23, 2015
Aptose Biosciences to Present at the 27th Annual ROTH Conference
March 5, 2015
Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014
March 3, 2015
Aptose Biosciences To Host Quarter and Seven Month Transition Period Ended December 31, 2014 Conference Call and Webcast
February 26, 2015
Aptose Biosciences to Present at the Cowen & Company 35th Annual Healthcare Conference
February 25, 2015
Aptose Biosciences to Present at the RBC Capital Markets 2015 Global Healthcare Conference
February 19, 2015
Aptose Biosciences Appoints Dr. Bradley Thompson to the Audit Committee
January 20, 2015
Aptose Biosciences Doses First Patient in Phase 1b Clinical Study of APTO-253 in Relapsed or Refractory Hematological Malignancies
January 13, 2015
Aptose Biosciences to Present at Biotech Showcase(TM) 2015
January 12, 2015
Aptose Biosciences Announces Appointment of Dr. Erich Platzer to Board of Directors
December 15, 2014
Aptose Biosciences Presents APTO-253 Preclinical Data at 56th American Society of Hematology Annual Meeting
December 9, 2014
Aptose Biosciences to Present at Oppenheimer & Co. 25th Annual Healthcare Conference
December 5, 2014
Aptose Biosciences to Present Preclinical Research Update for APTO-253 at the 56th American Society of Hematology Annual Meeting
December 3, 2014
Aptose Biosciences to Present at The Stifel 2014 Healthcare Conference
November 17, 2014
Aptose Biosciences reports results for the four months ended September 30, 2014
November 4, 2014
Aptose Biosciences To Host Conference Call and Webcast For Four Month Interim Period Ended September 30, 2014
October 30, 2014
Aptose Biosciences Announces Approval for Listing on the NASDAQ Capital Market Shares to Begin Trading Under the Symbol APTO
October 21, 2014
Aptose Biosciences to Present at the 2014 BIO Investor Forum
October 3, 2014
Aptose Biosciences Announces Reverse Stock Split
October 1, 2014
Aptose Biosciences Joins The Leukemia & Lymphoma Society's Groundbreaking Beat AML Research Initiative with Oregon Health & Science University
September 29, 2014
Aptose Biosciences to Present at Upcoming Investor Conferences
September 25, 2014
Aptose Biosciences Recruits Stephen B. Howell, M.D. to Act in the Capacity of Chief Medical Officer
September 8, 2014
Lorus Therapeutics Implements Name Change to Aptose Biosciences
September 2, 2014
Lorus Therapeutics Announces Results of Annual and Special Meeting of Shareholders
August 19, 2014
Lorus Therapeutics Proposes Name Change to "APTOSE BIOSCIENCES" and Share Consolidation for Potential NASDAQ Listing
July 15, 2014
Investment Industry Regulatory Organization of Canada - Trade Resumption - Lorus Therapeutics - LOR
June 21, 2011
Investment Industry Regulatory Organization of Canada - Trading Halt - Lorus Therapeutics - LOR
June 21, 2011
Investment Industry Regulatory Organization of Canada - Trade Resumption - Lorus Therapeutics Inc. - LOR
December 1, 2010
Investment Industry Regulatory Organization of Canada - Trading Halt - Lorus Therapeutics Inc. - LOR
December 1, 2010
Calls
The 5 newest of 14 calls. Every call is listed under its year.
- Aptose Biosciences (APTO) Q1 2024 Earnings Call
May 14, 2024
Transcript - Aptose Biosciences (APTO) Q4 2023 Earnings Call
Mar 26, 2024
Transcript - Aptose Biosciences (APTO) Q3 2023 Earnings Call
Nov 9, 2023
Transcript - Aptose Biosciences (APTO) Q2 2023 Earnings Call
Aug 10, 2023
Transcript - Aptose Biosciences (APTO) Q1 2023 Earnings Call
May 8, 2023
Transcript
Decks
The 5 newest of 7 decks. Every deck is listed under its year.
- Investor Presentation (March 2025)
Investor deck · 23 slides · Mar 12, 2025
- Investor Presentation (January 2025)
Investor deck · 20 slides · Jan 13, 2025
- Investor Presentation (July 2024)
Investor deck · 20 slides · Jul 26, 2024
- Investor Presentation (January 2023)
Investor deck · 36 slides · Jan 6, 2023
- Investor Presentation (July 2022)
Investor deck · 25 slides · Jul 20, 2022